Treatment ban remains: state government dismisses NHMRC advice on puberty blockers

The interim advice takes a different approach to the UK's Cass Review, which recommended restricting puberty blockers to clinical trials.

Queensland says it will not change its ban on puberty blockers for children with gender dysphoria in the face of new NHMRC guidance, which says clinicians should be free to decide on the treatment.

Released for public consultation on Monday, the interim guidance supports the use of puberty suppressants — specifically, gonadotropin-releasing hormone agonists — as a treatment option for children with gender incongruence, whether or not they experience gender dysphoria.

It effectively goes beyond the UK’s Cass Review recommendations from 2024, which said that puberty blockers should only be offered within the context of a clinical trial.

Federal Health Minister Mark Butler said the advice, based on a detailed literature review of their safety and efficacy, should inform state governments.